Compass Pathways plc announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company?s New York City office. Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy.

She played an integral role in bringing the company from clinical-stage to commercial-stage and was responsible for formulating commercial launch strategy and scaling the commercial organization. Over her career, Lori has launched multiple CNS-focused assets, at Axsome and at Amgen, where she spent nearly a decade in several global brand roles, including neuroscience and oncology/hematology, as well as roles in commercial strategy and operations, corporate strategy and business development. Lori?s appointment follows that of Teri Loxam as Chief Financial Officer in March 2024 and Dr. Michael Gold as Chief Research & Development Officer in May 2024.

All three executive team members bring decades of successful strategic leadership and highly relevant experience in drug development.